{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:24:10Z","timestamp":1784042650722,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Poor persistence to antihypertensive therapy is an important cause of treatment failure. Investigating persistence is especially important in countries with a high cardiovascular mortality, like Lithuania. The aim of this study was to describe the antihypertensive treatment at initiation, to determine the percentage of patients not being persistent with antihypertensive treatment after 1\u00a0year and to explore factors associated with non-persistence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this cohort study, data on dispensed prescription medicines from the Lithuanian National Health Insurance Fund (NHIF) were used. All adult patients with a diagnosis of hypertension having first antihypertensive dispensed in 2018 were included. Descriptive statistics was used to determine the number of patients started with monotherapy and combination therapy. Treatment choice by Anatomical Therapeutic Chemical (ATC) and number of active pharmaceutical ingredient (API) was described. Non-persistence was assessed using the anniversary method. Multivariate logistic regression was used to explore factors associated with non-persistence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 72,088 patients were included into the study, 56% started on monotherapy treatment, with 49% being dispensed an angiotensin converting enzyme inhibitor, and 44% started on combination therapy. Overall, 57% of patients were non-persistent after 1\u00a0year. Patients\u2019 gender and prescriber qualification showed no association with non-persistence. Younger patients, patients from rural area, patients started with monotherapy, and patients with no medication change had higher odds to become non-persistent.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The majority of patients were initiated with treatment following hypertension management guidelines, but it is of concern that over half of the patients were non-persistent to antihypertensive therapy in the first year.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-022-03369-0","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T22:37:39Z","timestamp":1659479859000},"page":"1687-1696","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Non-persistence to antihypertensive drug therapy in Lithuania"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6583-9999","authenticated-orcid":false,"given":"Indre","family":"Treciokiene","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nomeda","family":"Bratcikoviene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Gulbinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn","family":"Wettermark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Taxis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,2]]},"reference":[{"key":"3369_CR1","unstructured":"Cardiovascular diseases (CVDs). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds). Accessed 16 Nov 2021"},{"key":"3369_CR2","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1093\/eurheartj\/ehw468","volume":"37","author":"N Townsend","year":"2016","unstructured":"Townsend N, Wilson L, Bhatnagar P et al (2016) Cardiovascular disease in Europe 2016: an epidemiological update. Eur Heart J 37:3182\u20133183. https:\/\/doi.org\/10.1093\/eurheartj\/ehw468","journal-title":"Eur Heart J"},{"key":"3369_CR3","unstructured":"Cardiovascular diseases statistics (2021) Statistics Explained. https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=Cardiovascular_diseases_statistics. Accessed 16 Nov 2021"},{"key":"3369_CR4","unstructured":"Lithuania (2021) Institute for Health Metrics and Evaluation. http:\/\/www.healthdata.org\/lithuania. Accessed 16 Nov 2021"},{"key":"3369_CR5","unstructured":"Health Statistics (2021)\u00a0https:\/\/hi.lt\/html\/sv_statistika.htm. Accessed 31 Aug 2021"},{"key":"3369_CR6","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W et al (2018) 2018 ESC\/ESH Guidelines for themanagement of arterial hypertension. Eur Heart J 39:3021\u20133104","journal-title":"Eur Heart J"},{"key":"3369_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.medici.2017.07.004","volume":"53","author":"I Lisauskiene","year":"2017","unstructured":"Lisauskiene I, Garuoliene K, Gulbinovic J (2017) Utilization of cardiovascular medicines and cardiovascular mortality in Lithuania, Sweden and Norway in 2003\u20132012. Medicina (Kaunas) 53:259\u2013267. https:\/\/doi.org\/10.1016\/j.medici.2017.07.004","journal-title":"Medicina (Kaunas)"},{"key":"3369_CR8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.tcm.2019.05.003","volume":"30","author":"JM Flack","year":"2020","unstructured":"Flack JM, Adekola B (2020) Blood pressure and the new ACC\/AHA hypertension guidelines. Trends Cardiovasc Med 30:160\u2013164","journal-title":"Trends Cardiovasc Med"},{"key":"3369_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2478\/v10287-012-0003-3","volume":"18","author":"A Laucevi\u010dius","year":"2012","unstructured":"Laucevi\u010dius A, Kasiulevi\u010dius V, Jatu\u017eis D et al (2012) Lithuanian High Cardiovascular Risk (LitHiR) primary prevention programme - rationale and design. Semin Cardiovasc Med 18:1\u20136. https:\/\/doi.org\/10.2478\/v10287-012-0003-3","journal-title":"Semin Cardiovasc Med"},{"key":"3369_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.atherosclerosis.2020.02.025","volume":"299","author":"A Laucevi\u010dius","year":"2020","unstructured":"Laucevi\u010dius A, Rink\u016bnien\u0117 E, Petrulionien\u0117 \u017d et al (2020) Trends in cardiovascular risk factor prevalence among Lithuanian middle-aged adults between 2009 and 2018. Atherosclerosis 299:9\u201314. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.02.025","journal-title":"Atherosclerosis"},{"key":"3369_CR11","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1097\/HJH.0b013e328364ca4c","volume":"31","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K et al (2013) 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens 31:1925\u20131938. https:\/\/doi.org\/10.1097\/HJH.0b013e328364ca4c","journal-title":"J Hypertens"},{"key":"3369_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/1472-6963-8-133","volume":"8","author":"PH Liu","year":"2008","unstructured":"Liu PH, Der WJ (2008) Antihypertensive medication prescription patterns and time trends for newly-diagnosed uncomplicated hypertension patients in Taiwan. BMC Health Serv Res 8:133. https:\/\/doi.org\/10.1186\/1472-6963-8-133","journal-title":"BMC Health Serv Res"},{"key":"3369_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1161\/HYPERTENSIONAHA.120.15462","volume":"77","author":"J An","year":"2020","unstructured":"An J, Luong T, Qian L et al (2020) Treatment patterns and blood pressure control with initiation of combination versus monotherapy antihypertensive regimens. Hypertension 77:103\u2013113. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15462","journal-title":"Hypertension"},{"key":"3369_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/iprp.s124047","volume":"6","author":"TM Abegaz","year":"2017","unstructured":"Abegaz TM, Tefera YG, Abebe TB (2017) Antihypertensive drug prescription patterns and their impact on outcome of blood pressure in Ethiopia: a hospital-based cross-sectional study. Integr Pharm Res Pract 6:29\u201335. https:\/\/doi.org\/10.2147\/iprp.s124047","journal-title":"Integr Pharm Res Pract"},{"key":"3369_CR15","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41440-019-0238-2","volume":"42","author":"M Ohishi","year":"2019","unstructured":"Ohishi M, Yoshida T, Oh A et al (2019) Analysis of antihypertensive treatment using real-world Japanese data\u2014the retrospective study of antihypertensives for lowering blood pressure (REAL) study. Hypertens Res 42:1057\u20131067. https:\/\/doi.org\/10.1038\/s41440-019-0238-2","journal-title":"Hypertens Res"},{"key":"3369_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","volume":"16","author":"KT Mills","year":"2020","unstructured":"Mills KT, Stefanescu A, He J (2020) The global epidemiology of hypertension. Nat Rev Nephrol 16:223\u2013237","journal-title":"Nat Rev Nephrol"},{"key":"3369_CR17","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.3346\/jkms.2015.30.12.1800","volume":"30","author":"YM Ah","year":"2015","unstructured":"Ah YM, Lee JY, Choi YJ et al (2015) Persistence with antihypertensive medications in uncomplicated treatment-na\u00efve patients: effects of initial therapeutic classes. J Korean Med Sci 30:1800\u20131806. https:\/\/doi.org\/10.3346\/jkms.2015.30.12.1800","journal-title":"J Korean Med Sci"},{"key":"3369_CR18","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.2147\/PPA.S225444","volume":"13","author":"D Putignano","year":"2019","unstructured":"Putignano D, Orlando V, Monetti VM et al (2019) Fixed versus free combinations of antihypertensive drugs: analyses of real-world data of persistence with therapy in Italy. Patient Prefer Adherence 13:1961\u20131969. https:\/\/doi.org\/10.2147\/PPA.S225444","journal-title":"Patient Prefer Adherence"},{"key":"3369_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.amjmed.2009.08.008","volume":"123","author":"O Friedman","year":"2010","unstructured":"Friedman O, McAlister FA, Yun L et al (2010) Antihypertensive drug persistence and compliance among newly treated elderly hypertensives in Ontario. Am J Med 123:173\u2013181. https:\/\/doi.org\/10.1016\/j.amjmed.2009.08.008","journal-title":"Am J Med"},{"key":"3369_CR20","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1007\/s00228-013-1555-z","volume":"69","author":"M Qvarnstrom","year":"2013","unstructured":"Qvarnstrom M, Kahan T, Kieler H et al (2013) Persistence to antihypertensive drug treatment in Swedish primary healthcare. Eur J Clin Pharmacol 69:1955\u20131964. https:\/\/doi.org\/10.1007\/s00228-013-1555-z","journal-title":"Eur J Clin Pharmacol"},{"key":"3369_CR21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1742-1241.2007.01630.x","volume":"62","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Benedict A, Muszbek N et al (2008) The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 62:76\u201387. https:\/\/doi.org\/10.1111\/j.1742-1241.2007.01630.x","journal-title":"Int J Clin Pract"},{"key":"3369_CR22","unstructured":"OECD (2019) Lithuania: Country Health Profile 2019, State of Health in the EU. OECD Publishing, Paris\/European Observatory on Health Systems and Policies, Brussels. ISBN 9789264340787"},{"key":"3369_CR23","unstructured":"Subsystems of Information System \u201cSVEIDRA\u201d\u202f(2021) Kaunas Territorial Health Insurance Fund. https:\/\/www.ktlk.lt\/istaigoms\/is\/sveidra\/. Accessed 15 Sep 2021"},{"key":"3369_CR24","unstructured":"Lithuanian official statistics portal (2019) Indicators database. Resident population at the beginning of the year. https:\/\/osp.stat.gov.lt\/statistiniu-rodikliu-analize?indicator=S3R167#\/. Accessed 25 Nov 2019"},{"key":"3369_CR25","doi-asserted-by":"crossref","unstructured":"Gr\u00e9goire JP, Moisan J (2016) Assesment of adherence to drug treatement in database research. In: Drug utilization research: methods and applications. John Wiley & Sons, Incorporated., pp 369\u2013380","DOI":"10.1002\/9781118949740.ch36"},{"key":"3369_CR26","unstructured":"Changes in cardiovascular medicines utilization and morbidity and mortality from cardiovascular disease in Lithuania \/ Ingrida Lisauskien\u0117 - CENTRAL (2021)\u00a0https:\/\/www.lvb.lt\/primo-explore\/fulldisplay?docid=ELABAETD24614524&context=L&vid=ELABA&lang=lt_LT&search_scope=eLABa&adaptor=LocalSearchEngine&isFrbr=true&tab=default_tab&query=any,contains,lisausien\u0117&offset=0. Accessed 6 Oct 2021"},{"key":"3369_CR27","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1258\/jrsm.96.11.525","volume":"96","author":"T Walley","year":"2003","unstructured":"Walley T, Duggan AK, Haycox AR, Niziol CJ (2003) Treatment for newly diagnosed hypertension: patterns of prescribing and antihypertensive effectiveness in the UK. J R Soc Med 96:525\u2013531. https:\/\/doi.org\/10.1258\/jrsm.96.11.525","journal-title":"J R Soc Med"},{"key":"3369_CR28","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.3346\/jkms.2015.30.12.1800","volume":"30","author":"Y-M Ah","year":"2015","unstructured":"Ah Y-M, Lee J-Y, Choi Y-J et al (2015) Persistence with antihypertensive medications in uncomplicated treatment-naive patients: effects of initial therapeutic classes. J Korean Med Sci 30:1800\u20131806. https:\/\/doi.org\/10.3346\/jkms.2015.30.12.1800","journal-title":"J Korean Med Sci"},{"key":"3369_CR29","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/jch.13531","volume":"21","author":"M Stapff","year":"2019","unstructured":"Stapff M, Hilderbrand S (2019) First-line treatment of essential hypertension: a real-world analysis across four antihypertensive treatment classes. J Clin Hypertens 21:627\u2013634. https:\/\/doi.org\/10.1111\/jch.13531","journal-title":"J Clin Hypertens"},{"key":"3369_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharma1010001","volume":"1","author":"I Treciokiene","year":"2022","unstructured":"Treciokiene I, Bratcikoviene N, Gulbinovic J et al (2022) Trend of antihypertensive medicine use in the Baltic States between 2008 and 2018: a retrospective cross-national comparison. Pharmacoepidemiology 1:1\u201311. https:\/\/doi.org\/10.3390\/pharma1010001","journal-title":"Pharmacoepidemiology"},{"key":"3369_CR31","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1111\/bcp.14691","volume":"87","author":"A Potteg\u00e5rd","year":"2021","unstructured":"Potteg\u00e5rd A, Olesen M, Christensen B et al (2021) Who prescribes drugs to patients: a Danish register-based study. Br J Clin Pharmacol 87:2982\u20132987. https:\/\/doi.org\/10.1111\/bcp.14691","journal-title":"Br J Clin Pharmacol"},{"key":"3369_CR32","doi-asserted-by":"publisher","unstructured":"S Malo I Aguilar-Palacio C Feja et al (2021) Effect of patient and treatment factors on persistence with antihypertensive treatment: a population-based study PLoS One 16.\u00a0https:\/\/doi.org\/10.1371\/journal.pone.0245610","DOI":"10.1371\/journal.pone.0245610"},{"key":"3369_CR33","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00228-013-1607-4","volume":"70","author":"T Grimmsmann","year":"2014","unstructured":"Grimmsmann T, Himmel W (2014) Persistence of antihypertensive drug use in German primary care: a follow-up study based on pharmacy claims data. Eur J Clin Pharmacol 70:295\u2013301. https:\/\/doi.org\/10.1007\/s00228-013-1607-4","journal-title":"Eur J Clin Pharmacol"},{"key":"3369_CR34","doi-asserted-by":"publisher","unstructured":"Biffi A, Rea R, Iannaccone T et al (2020) Sex differences in the adherence of antihypertensive drugs: a systematic review with meta-analyses BMJ Open 10.\u00a0https:\/\/doi.org\/10.1136\/bmjopen-2019-036418","DOI":"10.1136\/bmjopen-2019-036418"},{"key":"3369_CR35","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1080\/00343404.2019.1623390","volume":"54","author":"N Potrafke","year":"2020","unstructured":"Potrafke N, Roesel F (2020) The urban\u2013rural gap in healthcare infrastructure: does government ideology matter? Reg Stud 54:340\u2013351. https:\/\/doi.org\/10.1080\/00343404.2019.1623390","journal-title":"Reg Stud"},{"key":"3369_CR36","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/j.1524-4733.2010.00761.x","volume":"13","author":"JP Gr\u00e9goire","year":"2010","unstructured":"Gr\u00e9goire JP, Sirois C, Blanc G et al (2010) Persistence patterns with oral antidiabetes drug treatment in newly treated patients - a population-based study. Value Heal 13:820\u2013828. https:\/\/doi.org\/10.1111\/j.1524-4733.2010.00761.x","journal-title":"Value Heal"},{"key":"3369_CR37","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2147\/PPA.S55382","volume":"8","author":"M Lemstra","year":"2014","unstructured":"Lemstra M, Alsabbagh MW (2014) Proportion and risk indicators of nonadherence to antihypertensive therapy: a meta-analysis. Patient Prefer Adherence 8:211\u2013218. https:\/\/doi.org\/10.2147\/PPA.S55382","journal-title":"Patient Prefer Adherence"},{"key":"3369_CR38","doi-asserted-by":"crossref","unstructured":"Burnier M (2018) Drug adherence in hypertension and cardiovascular protection, updates in hypertension and cardiovascular protection. Springer International Publishing AG, part of Springer Nature, p.180","DOI":"10.1007\/978-3-319-76593-8"},{"key":"3369_CR39","unstructured":"Regarding the rules for writing prescriptions and issuing (selling) medicinal products, medical devices (medical devices) and reimbursable medical aids in pharmacies to the population and storing paper prescriptions after dispensing (selling) medicinal pr (2021)\u00a0https:\/\/e-seimas.lrs.lt\/portal\/legalAct\/lt\/TAD\/TAIS.162242\/asr. Accessed 15 Sep 2021"},{"key":"3369_CR40","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/sj.jhh.1001873","volume":"19","author":"C Bourgault","year":"2005","unstructured":"Bourgault C, S\u00e9n\u00e9cal M, Brisson M et al (2005) Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens 19:607\u2013613. https:\/\/doi.org\/10.1038\/sj.jhh.1001873","journal-title":"J Hum Hypertens"},{"key":"3369_CR41","first-page":"31","volume":"160","author":"JJ Caro","year":"1999","unstructured":"Caro JJ, Salas M, Speckman JL et al (1999) Persistence with treatment for hypertension in actual practice. CMAJ 160:31\u201337","journal-title":"CMAJ"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03369-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03369-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03369-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T16:19:55Z","timestamp":1663431595000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03369-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,2]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["3369"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03369-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,2]]},"assertion":[{"value":"10 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was issued by Vilnius Regional Biomedical Research Ethics Committee in 2021. Permission number 2021\/2\u20131314\u02d7790.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}